Dr. Nimer on the Biggest Challenges of MDS

Stephen D. Nimer, MD
Published: Friday, May 01, 2015



Stephen D. Nimer, MD, Director, Professor of Medicine, Sylvester Comprehensive Cancer Center discusses the challenges of treating myelodysplastic syndromes (MDS).

Patients with MDS have a wide variety of survival outcome; some may live for years while others only for months. Understanding from the beginning the expected progression of each individual patient it is critical, says Nimer.

Although there are three FDA approved drugs for MDS, none are curative and when patients progress on these drugs the prognosis is poor. New drug are needed as well as additional understanding on how stem-cell transplantation and drug therapies can be combined, says Nimer.



Stephen D. Nimer, MD, Director, Professor of Medicine, Sylvester Comprehensive Cancer Center discusses the challenges of treating myelodysplastic syndromes (MDS).

Patients with MDS have a wide variety of survival outcome; some may live for years while others only for months. Understanding from the beginning the expected progression of each individual patient it is critical, says Nimer.

Although there are three FDA approved drugs for MDS, none are curative and when patients progress on these drugs the prognosis is poor. New drug are needed as well as additional understanding on how stem-cell transplantation and drug therapies can be combined, says Nimer.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x